CRTX Share Price

Open 9.48 Change Price %
High 9.54 1 Day 0.01 0.11
Low 9.48 1 Week 0.00 0.00
Close 9.49 1 Month 0.00 0.00
Volume 163312 1 Year 0.00 0.00
52 Week High 12.53
52 Week Low 0.00
CRTX Important Levels
Resistance 2 9.55
Resistance 1 9.52
Pivot 9.50
Support 1 9.46
Support 2 9.43
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DRYS 1.01 -36.48%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
MU 21.71 -2.73%
More..
NASDAQ USA Top Gainers Stocks
BGMD 0.07 133.33%
LOCM 0.09 50.00%
NFEC 1.28 40.66%
BASI 0.90 28.57%
URRE 2.68 27.62%
QKLS 0.14 27.27%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
GRVY 20.96 23.15%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Cornerstone Therapeutics Inc. (NASDAQ: CRTX)

CRTX Technical Analysis 1.5
As on 3rd Feb 2014 CRTX Share Price closed @ 9.49 and we RECOMMEND Buy for LONG-TERM with Stoploss of 8.84 & Sell for SHORT-TERM with Stoploss of 9.52 we also expect STOCK to react on Following IMPORTANT LEVELS.
CRTX Target for January
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
CRTX Other Details
Segment EQ
Market Capital 127880384.00
Sector Consumer Durables Major Pharmaceuticals
Industry
Offical website
CRTX Address
CRTX
N/A
CRTX Latest News
Chiesi completes acquisition of cardiovascular medications from The Medicines ...   Cardiovascular Business   - 30th Jun 16
Cary's Chiesi USA could pay up to $742M for cardiovascular products   Triangle Business Journal   - 22nd Jun 16
Chiesi Completes the Acquisition of Three Hospital Products -- Kengreal(R ...   Marketwired (press release)   - 22nd Jun 16
Patients With COPD May Soon Benefit From the Chiesi Farmaceutici's ...   Marketwired (press release)   - 07th Jun 16
Chiesi agrees to acquire cardiovascular medications from The Medicines Company   Cardiovascular Business   - 11th May 16
Cary's Chiesi acquires cardiovascular products from The Medicines Company   Triangle Business Journal   - 09th May 16
Significant PTAB decisions regarding Chiesi's drug CARDENE   Lexology (registration)   - 27th Apr 15
Chiesi USA Presents: Pioneering Innovative Research and Philanthropy in the ...   Marketwired (press release)   - 20th Feb 15
Neos Therapeutics Acquires all Commercialization and Profit Rights to Generic ...   Business Wire (press release)   - 08th Sep 14
Cornerstone Therapeutics Inc. Announces Name Change to Chiesi USA, Inc.   Marketwired (press release)   - 28th Apr 14
Interactive Technical Analysis Chart Cornerstone Therapeutics Inc. ( CRTX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Cornerstone Therapeutics Inc.
CRTX Business Profile
Cornerstone Therapeutics Inc. is a specialty pharmaceutical company focused on commercializing products for the hospital, respiratory and related specialty markets. The Company�s promoted products include CUROSURF, ZYFLO CR, FACTIVE and SPECTRACEF. On December 30, 2011, the Company acquired Cardiokine, Inc., a specialty pharmaceutical company, focused on developing hospital products for cardiovascular indications. In March 2012, it acquired the North American product rights for FACTIVE (Gemifloxacin Mesylate) tablets. In June 2012, the Company acquired EKR Therapeutics, Inc. In February 2014, Chiesi Farmaceutici S.p.A acquired Cornerstone Therapeutics Inc.